Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Sugar acid

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44344   clinical trials with a EudraCT protocol, of which   7373   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    23 result(s) found for: Sugar acid. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2021-000667-74 Sponsor Protocol Number: CV006 Start Date*: 2021-11-30
    Sponsor Name:Medisch Centrum Leeuwarden BV
    Full Title: The effect of bile acid binding with colesevelam on postprandial glucose concentrations in patients after RYGB and cholecystectomy : a meal test study
    Medical condition: Post Bariatric Hypoglycemia
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004861 10059038 Postprandial hypoglycemia LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-022791-31 Sponsor Protocol Number: D01092010AZNTG Start Date*: Information not available in EudraCT
    Sponsor Name:University Erlangen-Nuremberg
    Full Title: Contrast sensitivity of patients with normal tension glaucoma by application of Azarga®
    Medical condition: The effect of AZARGA(R) on the central and spacial-temporal contrast sensitivity of patients with normal tension glaucoma will be examined. Healthy controls are required to prove the disease specif...
    Disease: Version SOC Term Classification Code Term Level
    12.1 10019279 Heart failure LLT
    12.1 10003555 Asthma bronchial LLT
    12.1 10021005 Hypoglycemia LLT
    12.1 10000456 Acid base balance LLT
    12.1 10054844 Anaphylactic reaction to drug LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-001263-73 Sponsor Protocol Number: 30-01-2012_1 Start Date*: 2012-05-25
    Sponsor Name:UZ Leuven
    Full Title: Involvement of corticotrophin-releasing hormone (CRH) and mucosal mast cells in stress-induced changes in intestinal permeability in healthy volunteers.
    Medical condition: Stress-induced intestinal hyperpermeability
    Disease: Version SOC Term Classification Code Term Level
    14.1 10037175 - Psychiatric disorders 10001039 Acute reaction to stress LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2011-003633-33 Sponsor Protocol Number: MAXEPA01 Start Date*: 2011-09-29
    Sponsor Name:Central Manchester University Hospitals NHS Foundation Trust
    Full Title: The effect of purified fish oils on glucose regulation in Congenital Hyperinsulinism of Infancy (CHI)
    Medical condition: Congenital hyperinsulinism
    Disease: Version SOC Term Classification Code Term Level
    14.0 10010331 - Congenital, familial and genetic disorders 10062329 Congenital endocrine anomaly PT
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2019-001216-38 Sponsor Protocol Number: 67369 Start Date*: 2019-06-12
    Sponsor Name:Hvidovre Hospital, Region Hovedstaden
    Full Title: Measurement of systemic pH and lactate in labouring women after intake of bicarbonate.
    Medical condition: A successful Labour is dependent on the ability of the uterus to produce co-ordinated contractions that are of both the right duration and intensity. A failure to produce these can result in an arr...
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004868 10036873 Prolonged labour, unspecified LLT
    Population Age: Adults Gender: Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2014-001733-86 Sponsor Protocol Number: 1710 Start Date*: 2014-10-15
    Sponsor Name:Maastricht University
    Full Title: The effect of L-arginine on brown adipose tissue metabolism in South Asian and white Caucasian subjects
    Medical condition: Obesity, glucose intolerance, endothelial dysfunction
    Disease:
    Population Age: Adults Gender: Male
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-004370-34 Sponsor Protocol Number: POM-003 Start Date*: 2018-04-09
    Sponsor Name:Amicus Therapeutics, Inc.
    Full Title: A Prospective Study in Subjects with Late-onset Pompe Disease who are Currently Being Treated with Enzyme Replacement Therapy
    Medical condition: Late-onset Pompe disease (LOPD) in subjects receiving standard-of-care enzyme replacement therapy (ERT)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10075702 Pompe's disease late onset LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Prematurely Ended) HU (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-000815-13 Sponsor Protocol Number: DIA-644-HOL-005-I Start Date*: 2008-09-29
    Sponsor Name:Technical University Munich
    Full Title: Analysis of cerebral, renal, peripheral, and retinal hemodynamics in adults with type 2 diabetes before, during, and after administration of pioglitazone or placebo.
    Medical condition: Considering the existing data, Actos (pioglitazone) is a promising candidate to improve hemodynamics of various vascular beds by positive effects on endothelial function. This study aims to analyse...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10012601 Diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-000755-40 Sponsor Protocol Number: ATB200-03 Start Date*: 2019-04-08
    Sponsor Name:Amicus Therapeutics, Inc.
    Full Title: A Phase 3 Double-blind Randomized Study to Assess the Efficacy and Safety of Intravenous ATB200 Co-administered With Oral AT2221 in Adult Subjects With Late Onset Pompe Disease Compared With Algluc...
    Medical condition: Adult Subjects With Late Onset Pompe Disease (LOPD)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10075702 Pompe's disease late onset LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) DK (Completed) GB (GB - no longer in EU/EEA) SE (Completed) HU (Completed) BE (Completed) SK (Completed) ES (Completed) NL (Completed) BG (Prematurely Ended) SI (Completed) GR (Completed) AT (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2011-000942-39 Sponsor Protocol Number: NL34476.068.11 Start Date*: 2011-06-20
    Sponsor Name:CTMM, the Center for Translational Molecular Medicine
    Full Title: Effects of thyroid hormone treatment on mitochondrial function, ectopic fat accumulation, insulin sensitivity and brown adipose tissue in type 2 diabetes mellitus.
    Medical condition: This trial includes overweight patients with both hypothyroidism and type 2 diabetes.
    Disease: Version SOC Term Classification Code Term Level
    13.1 10014698 - Endocrine disorders 10021114 Hypothyroidism PT
    13.1 10027433 - Metabolism and nutrition disorders 10045242 Type II diabetes mellitus LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-004019-29 Sponsor Protocol Number: CRACCA-2019 Start Date*: 2021-07-15
    Sponsor Name:Dipartimento di Medicina-DIMED, università di Padova
    Full Title: Medical combination therapy with retinoic acid and cabergoline in ACTH-secreting pituitary adenoma: a prospective and randomized study.
    Medical condition: Cushing's disease in patients in whom pituitary surgery has not been curative or in situations where it is contraindicated or refused by patient.
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004860 10011651 Cushing's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2015-003873-13 Sponsor Protocol Number: ESR-14-10613/D1690L00044 Start Date*: 2016-02-25
    Sponsor Name:Institute for the Study, Research and Education in Diabetes Mellitus and Metabolic Disorders
    Full Title: Evaluation of the tubular effects of dapagliflozin using 1HNMR spectroscopy.
    Medical condition: Diabetes mellitus type 2.
    Disease: Version SOC Term Classification Code Term Level
    18.1 10027433 - Metabolism and nutrition disorders 10012601 Diabetes mellitus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-001115-73 Sponsor Protocol Number: Regenerate-1 Start Date*: 2018-06-05
    Sponsor Name:Uppsala University Hospital
    Full Title: A Phase I/II, 2-Arm, Open Label, Single Centre Study to Investigate the Safety and Effect of Oral GABA Therapy on β-cell Regeneration in Type 1-diabetes Patients
    Medical condition: Type 1 diabetes
    Disease: Version SOC Term Classification Code Term Level
    20.0 10027433 - Metabolism and nutrition disorders 10067584 Type 1 diabetes mellitus PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: View results
    EudraCT Number: 2016-001793-15 Sponsor Protocol Number: Gastro_CHU_16-1 Start Date*: 2016-07-12
    Sponsor Name:LactoResearch sprl
    Full Title: PROSPECTIVE STUDY OF THE EFFICIENCY OF PROBIOTIC MIXTURE TO IMPROVE LACTOSE DIGESTION AND SYMPTOMS OF LACTOSE INTOLERANCE
    Medical condition: lactose intolerance
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004861 10023682 Lactose intolerant LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-000954-67 Sponsor Protocol Number: ATB200-07 Start Date*: 2020-04-08
    Sponsor Name:Amicus Therapeutics, Inc.
    Full Title: A Phase 3 Open-label Extension Study to Assess the Long-term Safety and Efficacy of Intravenous ATB200 Co-administered With Oral AT2221 in Adult Subjects With Late-onset Pompe Disease
    Medical condition: Adult Subjects With Late Onset Pompe Disease (LOPD)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10075702 Pompe's disease late onset LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) ES (Ongoing) DE (Completed) DK (Trial now transitioned) FR (Trial now transitioned) BE (Trial now transitioned) GR (Trial now transitioned) SI (Trial now transitioned) AT (Completed) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2011-000624-16 Sponsor Protocol Number: LOEWE_B4 Start Date*: 2011-11-28
    Sponsor Name:Justus Liebig Universität Gießen
    Full Title: Infertility and inflammatory urogenital diseases as a result of the metabolic syndrome Male infertility with infection and inflammation -MIBIE-
    Medical condition: infertility and inflammatory urogenital diseases as a result of the metabolic syndrome
    Disease: Version SOC Term Classification Code Term Level
    14.0 10038359 - Renal and urinary disorders 10046694 Urogenital disorder PT
    14.0 10027433 - Metabolism and nutrition disorders 10052066 Metabolic syndrome PT
    14.0 10038604 - Reproductive system and breast disorders 10021926 Infertility PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-001381-96 Sponsor Protocol Number: LG_T1_EGP Start Date*: 2014-06-17
    Sponsor Name:Medizinische Universität Graz / Endokrinologie und Stoffwechsel
    Full Title: A randomized, double blind, two-period cross-over trial investigating the effect of liraglutide as add on to intensive insulin treatment on the endogenous glucose production in subjects with C-pept...
    Medical condition: Diabetes Mellitus Type 1
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2013-003296-34 Sponsor Protocol Number: OTX116505 Start Date*: 2014-01-29
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: A Single Blind, Randomised, Placebo Controlled, Repeat Dose, Dose Escalating Study Investigating Safety, Tolerability Pharmacokinetics, Pharmacodynamics and the Beta-Cell Preserving Effect of Oteli...
    Medical condition: NOT1DM is an autoimmune disease. This means that the immune system, the part of the body which usually helps to fight infections, mistakenly attacks cells that produce insulin in the body. Insulin ...
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004870 10003814 Autoimmune disease, not elsewhere classified LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2016-002023-28 Sponsor Protocol Number: N/2015/70 Start Date*: 2018-06-04
    Sponsor Name:CHU Besançon
    Full Title: Prevention of new onset diabetes after transplantation by a short term treatment of Vildagliptin in the early post-transplant period
    Medical condition: Transplanté rénal à haut risque de développer un diabète de novo
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038359 - Renal and urinary disorders 10038359 Renal and urinary disorders SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2015-001760-19 Sponsor Protocol Number: THR-1442-C-476 Start Date*: 2016-01-07
    Sponsor Name:Theracos Sub, LLC
    Full Title: A double blind placebo controlled study to evaluate the effects of bexagliflozin on hemoglobin A1c in patients with type 2 diabetes and increased risk of cardiovascular adverse events
    Medical condition: Type II diabetes
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004861 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) DE (Completed) PL (Completed) DK (Completed) NL (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA